GLP-1 (glucagon-like peptide-1) receptor agonists, such as Semaglutide , are a class of medications originally developed for the treatment of type 2 diabetes but have also gained recognition for their role in weight management
It means what were doing isnt working
Its primary compound patent (US 9,474,780) is not set to expire until January 5, 2036
Coverage depends on your insurance plan, medical criteria, and prior authorization requirements
Studies show that intermittent fasting, paired with GLP-1 therapy, leads to significant weight loss, improved insulin sensitivity, and metabolic efficiency
Effects on alcohol cravings may appear at lower doses, potentially allowing users to maintain reduced consumption benefits without escalating to maximum doses